{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:08:13Z","timestamp":1786993693191,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.lungcan.2017.10.011","type":"journal-article","created":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T16:21:26Z","timestamp":1509121286000},"page":"5-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors"],"prefix":"10.1016","volume":"115","author":[{"given":"Junhong","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangzhi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang W.","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lungcan.2017.10.011_bib0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.lungcan.2017.10.011_bib0010","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin. Proc."},{"issue":"1","key":"10.1016\/j.lungcan.2017.10.011_bib0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/JTO.0b013e31815e8b60","article-title":"EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers","volume":"3","author":"Inamura","year":"2008","journal-title":"J. Thorac. Oncol."},{"issue":"13","key":"10.1016\/j.lungcan.2017.10.011_bib0020","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1158\/1078-0432.CCR-08-0168","article-title":"EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer","volume":"14","author":"Koivunen","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"15","key":"10.1016\/j.lungcan.2017.10.011_bib0025","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1158\/1078-0432.CCR-13-0318","article-title":"ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer","volume":"19","author":"Gainor","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"November (3)","key":"10.1016\/j.lungcan.2017.10.011_bib0030","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/path.4950","article-title":"Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer","volume":"243","author":"Noh","year":"2017","journal-title":"J. Of pathol."},{"key":"10.1016\/j.lungcan.2017.10.011_bib0035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fonc.2012.00017","article-title":"ALK inhibitors, a pharmaceutical perspective","volume":"2","author":"Ardini","year":"2012","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2017.10.011_bib0040","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1111\/j.1349-7006.2008.00972.x","article-title":"Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer","volume":"99","author":"Mano","year":"2008","journal-title":"Cancer Sci."},{"issue":"6","key":"10.1016\/j.lungcan.2017.10.011_bib0045","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.cell.2007.11.025","article-title":"Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer","volume":"131","author":"Rikova","year":"2007","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.lungcan.2017.10.011_bib0050","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1158\/1078-0432.CCR-08-3248","article-title":"KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer","volume":"15","author":"Takeuchi","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.lungcan.2017.10.011_bib0055","doi-asserted-by":"crossref","first-page":"e31323","DOI":"10.1371\/journal.pone.0031323","article-title":"KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only","volume":"7","author":"Togashi","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.lungcan.2017.10.011_bib0060","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/JTO.0000000000000087","article-title":"HIP1-ALK, a novel ALK fusion variant that responds to crizotinib","volume":"9","author":"Fang","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2017.10.011_bib0065","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/JTO.0000000000000093","article-title":"A novel fusion of TPR and ALK in lung adenocarcinoma","volume":"9","author":"Choi","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2017.10.011_bib0070","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.canlet.2015.03.028","article-title":"Novel ALK fusion partners in lung cancer","volume":"362","author":"Iyevleva","year":"2015","journal-title":"Cancer Lett."},{"issue":"23","key":"10.1016\/j.lungcan.2017.10.011_bib0075","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.lungcan.2017.10.011_bib0080","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10072","key":"10.1016\/j.lungcan.2017.10.011_bib0085","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.lungcan.2017.10.011_bib0090","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S1470-2045(15)00614-2","article-title":"Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial","volume":"17","author":"Kim","year":"2016","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2017.10.011_bib0095","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(15)00488-X","article-title":"i. study, Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial","volume":"17","author":"Shaw","year":"2016","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2017.10.011_bib0100","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nm.2673","article-title":"Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies","volume":"18","author":"Lipson","year":"2012","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.lungcan.2017.10.011_bib0105","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1097\/JTO.0b013e3182614ab5","article-title":"Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer","volume":"7","author":"Peled","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"15","key":"10.1016\/j.lungcan.2017.10.011_bib0110","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"issue":"14","key":"10.1016\/j.lungcan.2017.10.011_bib0115","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"issue":"5","key":"10.1016\/j.lungcan.2017.10.011_bib0120","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ng.806","article-title":"A framework for variation discovery and genotyping using next-generation DNA sequencing data","volume":"43","author":"DePristo","year":"2011","journal-title":"Nat. Genet."},{"issue":"23","key":"10.1016\/j.lungcan.2017.10.011_bib0125","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1093\/bioinformatics\/btu549","article-title":"FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution","volume":"30","author":"Newman","year":"2014","journal-title":"Bioinformatics"},{"issue":"1","key":"10.1016\/j.lungcan.2017.10.011_bib0130","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nbt.1754","article-title":"Integrative genomics viewer","volume":"29","author":"Robinson","year":"2011","journal-title":"Nat. Biotechnol."},{"issue":"12","key":"10.1016\/j.lungcan.2017.10.011_bib0135","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1093\/nar\/gnh094","article-title":"A simple, rapid, high-fidelity and cost-effective PCR-based two-step DNA synthesis method for long gene sequences","volume":"32","author":"Xiong","year":"2004","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"10.1016\/j.lungcan.2017.10.011_bib0140","doi-asserted-by":"crossref","first-page":"6711","DOI":"10.1128\/MCB.13.11.6711","article-title":"Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase","volume":"13","author":"Rodrigues","year":"1993","journal-title":"Mol. Cell. Biol."},{"issue":"6","key":"10.1016\/j.lungcan.2017.10.011_bib0145","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/sj.onc.1201596","article-title":"Role of the TFG N-terminus and coiled-coil domain in the transforming activity of the thyroid TRK-T3 oncogene","volume":"16","author":"Greco","year":"1998","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.lungcan.2017.10.011_bib0150","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/sj.onc.1204127","article-title":"The RFG oligomerization domain mediates kinase activation and re-localization of the RET\/PTC3 oncoprotein to the plasma membrane","volume":"20","author":"Monaco","year":"2001","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.lungcan.2017.10.011_bib0155","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrc3580","article-title":"Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology","volume":"13","author":"Hallberg","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"5151","key":"10.1016\/j.lungcan.2017.10.011_bib0160","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.lungcan.2017.10.011_bib0165","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S0046-8177(96)90167-7","article-title":"Detection of the t(2;5)(p23;q35) chromosomal translocation in large B-cell lymphomas other than anaplastic large cell lymphoma","volume":"27","author":"Arber","year":"1996","journal-title":"Hum. Pathol."},{"issue":"9","key":"10.1016\/j.lungcan.2017.10.011_bib0170","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1158\/1541-7786.MCR-08-0522","article-title":"Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers","volume":"7","author":"Lin","year":"2009","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.lungcan.2017.10.011_bib0175","first-page":"145","article-title":"Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib","volume":"8","author":"El-Osta","year":"2015","journal-title":"Pharmgenomics Pers. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2017.10.011_bib0180","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2183\/pjab.91.193","article-title":"The EML4-ALK oncogene: targeting an essential growth driver in human cancer","volume":"91","author":"Mano","year":"2015","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"issue":"6","key":"10.1016\/j.lungcan.2017.10.011_bib0185","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1097\/JTO.0000000000000467","article-title":"BIRC6-ALK, a novel fusion gene in ALK break-apart FISH-negative lung adenocarcinoma, responds to crizotinib","volume":"10","author":"Shan","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2017.10.011_bib0190","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02149-2016","article-title":"Identification of a novel crizotinib-sensitive BCL11A-ALK gene fusion in a nonsmall cell lung cancer patient","volume":"49","author":"Tian","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"18","key":"10.1016\/j.lungcan.2017.10.011_bib0195","doi-asserted-by":"crossref","first-page":"5609","DOI":"10.1158\/1078-0432.CCR-08-2762","article-title":"Inhibition of ALK signaling for cancer therapy","volume":"15","author":"Mosse","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.lungcan.2017.10.011_bib0200","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMoa1007478","article-title":"EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors","volume":"363","author":"Choi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2017.10.011_bib0205","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-11-2906","article-title":"Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer","volume":"18","author":"Doebele","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"120","key":"10.1016\/j.lungcan.2017.10.011_bib0210","doi-asserted-by":"crossref","first-page":"120ra17","DOI":"10.1126\/scitranslmed.3003316","article-title":"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers","volume":"4","author":"Katayama","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"18","key":"10.1016\/j.lungcan.2017.10.011_bib0215","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/0008-5472.CAN-11-1340","article-title":"A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors","volume":"71","author":"Sasaki","year":"2011","journal-title":"Cancer Res."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217305500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217305500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,26]],"date-time":"2018-08-26T08:24:08Z","timestamp":1535271848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500217305500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":43,"alternative-id":["S0169500217305500"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.10.011","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}